U.S. regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find ...

The Food and Drug Administration (FDA) has cleared Lumipulse G for U.S. commercialization as the first blood-based test that ...

The FDA has approved the Lumipulse Plasma Ratio test, a groundbreaking blood test for early dementia detection. This less ...

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.

The test can aid doctors in determining whether a patient’s memory problems are due to Alzheimer’s or a number of other ...

The Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator ...

Lecanemab binds with high affinity to soluble amyloid-beta protofibrils. It won full FDA approval in July 2023 based on trial ...

The findings show that memory clinics can have “the infrastructure and expertise to safely administer and care for patients ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

Suddenly, new therapies became far more expensive to finance. A lackluster launch of Alzheimer’s drug Leqembi also spooked investors. So did recent staffing cuts at the U.S. Food and Drug ...

PHILHEALTH executives, led by its acting president and CEO, Dr. Edwin Mercado, speaks with officials and staff of St. Paul’s Hospital Iloilo on Tuesday, April 29, 2025. Mercado encouraged the ...